Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens

BACKGROUND: Plasmodium vivax malaria is a major cause of morbidity and recognised as an important contributor to mortality in some endemic areas. The current recommended treatment regimen for the radical cure of P. vivax includes a schizontocidal antimalarial, usually chloroquine, combined with a 14...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672497/
https://www.ncbi.nlm.nih.gov/pubmed/26643116
http://dx.doi.org/10.1186/s12879-015-1276-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672497/
https://www.ncbi.nlm.nih.gov/pubmed/26643116
http://dx.doi.org/10.1186/s12879-015-1276-2

Ejemplares similares